Selvita S.A. (WSE: SLV), the largest drug discovery company in Central and Eastern Europe, today announced that Pawel Przewiezlikowski, Chief Executive Officer of the company, will present at the upcoming 17th Annual BIO CEO & Investor Conference, which will take place on February 9 -10, at the Waldorf Astoria New York.
Mr Przewiezlikowski will present on Tuesday, February 10, at 11:00 a.m. in the Duke Windsor room, providing a corporate overview of the Company’s recent activities, including its transition to the Warsaw Stock Exchange Main Market, strategic plans concerned with the development of its R&D programs targeting PIM/FLT3 and CDK8 kinases in oncology, strategic discovery collaborations with Merck Serono, H3 Biomedicine and Felicitex Therapeutics, as well as the further growth of Selvita’s research service business.
A live audio webcast of the Selvita presentation will be accessible at: http://www.veracast.com/webcasts/bio/ceoinvestor2015/66212271148.cfm
The audio webcast will be archived shortly after the live event and will be available for 90 days through the Selvita website –http://www.selvita.com/investor-relations/educational-and-analytical-materials/presentations.